UNITED STATES SECURITIES AND EXCHANGE COMMISSION  WASHINGTON, D.C. 20549  FORM 10-QSB/A  [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2001  [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from __________________ to __________________  Commission File Number 0-23957   MEDITECNIC,  INC. (Exact Name of small business issuer as specified in its charter)  Nevada 87-0430532 (State or other Jurisdiction of I.R.S. Employer Identi- Incorporation or Organization fication No.)  24351 Pasto Road, #B, Dana Point, California 92629 (Address of Principal Executive Offices) (Zip Code)  (949) 489-2400 (Issuer's Telephone Number, including Area Code)  Indicate by check mark whether the Registrant (i) has filed all reports required to be filed by Section 13, or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (of for such shorter period that the Registrant was required to file such reports) and (ii) has been subject to such filing requirements for the past 90 days.  YesNo X Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. YesNo __X__ Indicate the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date.  Common Stock, par value  $.001 7,527,485 Title of Class Number of Shares outstanding at October 6, 2008 Transitional Small Business Format     Yes     No X         Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION  The Company  had no sales in the three months ended March 31, 2001 and 2000. Our net loss was $46,983 for the three months ended March  31, 2001, compared to $33,204 in 2000.  The Company invests cash in marketable securities. A portion of the Companys assets are valued in currencies other than the US dollar, primarily Swiss francs. We recognize gains and losses on the currency exchange rate changes from time to time.  The Company is in the research and development stage of its products.  Research and development costs were $10,703 for the three months ended March 31, 2001, compared to  $30,046 for the 2000 period.   Research and development is carried out by a non affiliated entity, Meditecnic SA, on a contract basis.  The Company has an option to purchase all of the capital stock of Meditecnic SA for CHF 400,000 granted November 5, 1999, of which CHF 300,000 ($195,720) was paid in November 1999 and is accounted for as a deposit. We purchased a patent from Meditecnic  in the 2001 quarter for $110,706, and loaned Meditecnic $243,528 in the 2001 quarter. The Company closed on the acquisition of Meditecnic on September 12, 2001. In addition the Company placed a CHF 60,000 deposit for the purchase of patents in December 1999 ($38,346) and a CHF 100,000 ($60,390) for the purchase of an additional patent in February 2000.  The Company had cash on hand and marketable securities of $1,507,268 at March 31, 2001, which is believed to be sufficient to fund the Companys operations until at least the end of fiscal 2002.  The financial statements for the years ended 2000 and 1999 were previously audited by the Companys former independent auditors. In the process of preparing its financial statements for the years ended December 31, 2001 and going forward, the Companys Board of Directors decide d to engage its new independent auditors to re-audit the financial statements for 2000 and 1999, because the new independent auditor was unable to obtain access to the prior audit work papers of the former auditing firm, which was no longer in existence.  Information included in this annual report  includes forward looking statements, which can be identified by the use of forward-looking terminology such as may, expect, anticipate, believe, estimate, or continue, or the negative thereof or other variations thereon or comparable terminology. The statements in "Risk Factors" and other statements and disclaimers in this registration statement constitute cautionary statements identifying important factors, including risks and uncertainties, relating to the forward-looking statements that could cause actual results to differ materially from those reflected in the forward-looking statements.  Since we have not yet generated any revenues, we are a development stage company as that term is defined in paragraphs 8 and 9 of SFAS No. 7.   Our auditors have included an explanatory paragraph in their report on our financial statements, relating to the uncertainty of our business as a going concern, due to our lack of operating history or current revenues and competitive position.  We do not believe that conventional financing, such as bank loans, is available to us due to these factors.  We have no bank line of credit available to us.  Management believes that it will be able to raise the required funds for operations from one or more future offerings, in order to effect our business plan.  Our future operating results are subject to many facilities, including:  o     our success in developing our technology;  o     our ability to obtain customers for our devices;  o     the effects of competition;  o     our ability to obtain additional financing; and  o     other risks which we identify in future filings with the SEC.  Any or all of our forward looking statements in this annual report and in any other public statement we make may turn out to be wrong. They can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. Consequently, no forward looking statement can be guaranteed. In addition, we undertake no responsibility to update any forward-looking statement to reflect events or circumstances which occur after the date of this report.        MEDITECNIC, INC. (A DEVELOPMENT STAGE COMPANY) BALANCE SHEET AS OF DECEMBER 31, 2000 AND MARCH 31, 2001  March 31 December 31 ASSETS 2001 2000  Current Assets Cash and Cash Equivalents $ 598,606 $ 740,278 Interest Receivable 4,855 4,855 Prepaid Expenses 11,356 11,356 Marketable Securities 740,390 766,990 Total Current Assets $ 1,355,207 $ 1,523,479  Other Assets Patents 872,326 761,620 Refundable Deposits 296,896 296,896 Total Other Assets 1,169,222 1,058,516  Total Assets $ 2,524,429 $ 2,581,995  LIABILIITES AND STOCKHOLDERS EQUITY Current Liabilities Accounts Payable 16,079 -- Total Current Liabilities 16,079 --  Stockholders Equity Preferred Stock (1,000 shares issued and outstanding) 1 1 Capital Stock (7,527,485 issued and outstanding) 7,528 7,528 Additional Paid In Capital 3,075,055 3,075,555 Accumulated Deficit During the Development Stage (659,119) (612,137) Accumulated Other Comprehensive Income 84,887 111,549 2,508,352 2,581,995  Total Liabilities and Stockholders Equity $ 2,524,431 $ 2,581,995          See accompanying Notes to Financial Statements.      MEDITECNIC, INC. (A DEVELOPMENT STAGE COMPANY) STATEMENTS OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31, 2001 AND 2000 AND CUMULATIVE FROM MARCH 24, 1998 TO MARCH 31, 2001 Cumulative March 31 March 31 1998 TO Income 2001 2000 2001 Sales Turnover $ -- $ -- $ 59,864 Research and Development -- -- 357,332 Realization of Patents -- -- 90,734 Product Sales -- -- 3,733 Total Income -- -- 511,663  Operating Expenses General and Administrative 7,241 1,500 128,597 Bank Charges 155 280 34,249 Audit Fees 5,000 -- 11,335 Marketing and Advertising -- -- 1,014 Other Financial Charges -- -- 55,853 Legal and Honoraries Fees 66 -- 6,149 Research and Development 10,703 30,046 694,774 Translation Fees -- 1,378 2,182 Patent Fees 19,156 -- 31,836 Travel Expenses -- -- -- Depreciation -- -- -- Amortization -- -- -- Staff Research -- -- 229,604 Office Expense -- -- -- Small Materials and Supplies -- -- -- Postage -- -- -- Insurance  Business -- -- -- Promotions and Seminars -- -- -- Telephone -- -- -- Office Rent -- -- -- Utilities -- -- -- Repairs and Maintenance -- -- -- Total Operating Expenses 42,321 33,204 1,195,593  Net Operating Income (Loss) (42,321) (33,204) (683,930)  Other Income (Expense) Interest Income -- -- 36,774 Interest Expense -- -- (7,301) Other Taxes (4,662) -- (4,662) Total Other Income (Expense) (4,662) -- 24,811  Net Income (Loss) $ (46,983) $ (33,204) $ (659,119)  Other Comprehensive Income (Loss) Gains (Losses) on Exchange Rates (62) 762 37,843 Gain (Loss) in Marketable Securities (26,600) 21,270 47,404 Net Comprehensive Income (Loss) (26,662) 22,032 84,887  Net Income (Loss) per share $ (0) $ (0.0044) $ -- See accompanying Notes to Financial Statements.       MEDITECNIC, INC. (A DEVELOPMENT STAGE COMPANY) STATEMENTS OF CASH FLOWS FOR THE THREE MONTHS ENDED MARCH 31, 2001 AND 2000 AND CUMULATIVE FROM MARCH 24, 1998 TO MARCH 31, 2001  Cumulative March 31 March 31 1998 TO CASH FLOWS FROM OPERATING ACTIVITIES 2001 2000 2001 Net Income $ (46,983) $ (33,204) $ (659,119)  Adjustments to reconcile net income to net cash provided by operating activities Depreciation -- -- -- Amortization -- -- -- Increase (decrease) in: Interest Receivable -- 4,743 (4,855) Prepaid Expenses -- -- (11,356) Increase (decrease) in: Accounts Payable 16,079 -- 16,079 Other Comprehensive Income (26,662) 22,032 84,887 Net Cash Provided (Used) By Operating Activities (57,566) (6,429) (574,364)  CASH FLOWS FROM INVESTING ACTIVITIES  Cash Used for Deposit -- (62,830) (296,896) Cash Used of Patent Acquisition (110,706) (60,390) (872,327) Increase (decrease) in Marketable Securities 26,600 (21,270) (751,719) Net Cash (Used) By Investing Activities (84,106) (144,490) (1,920,941)  CASH FLOWS FROM FINANCING ACTIVITIES  Sale of Common Stock -- -- 3,082,583 Net Cash (Used) By Financing Activities -- -- 3,082,583  NET INCREASE (DECREASE) IN CASH (141,672) (150,919) 598,606  CASH AT BEGINNING OF PERIOD 740,278 267,820 --  CASH AT END OF PERIOD $ 598,606 $ 116,901 $ 598,606  Cash Paid for Interest -- -- 7,301              See accompanying Notes to Financial Statements.  MEDITECNIC, INC. (A Development Stage Company) NOTES TO CONDENSED FINANCIAL STATEMENTS (UNAUDITED) MARCH 31, 2001   Item 1.       Comments  The accompanying financial statements are unaudited, but in the opinion of the management of the Company, contain all adjustments, consisting of only normal recurring accruals, necessary to present fairly the financial position at  March 31, 2001, the results of operations for the three months ended March 31,  2001 and 2000, and the cash flows for the three months ended March 31, 2001 and 2000.  Reference is made to the Company's Form 10-KSB for the year ended December 31, 2000.  The results of operations for the three months ended March 31, 2001 are not necessarily indicative of the results of operations to be expected for the full fiscal year ending December 31, 2001.  Item 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION  The Company's research and development efforts continued in the first quarter of 2001.  Additional patents were purchased from Meditecnic SA, who performs research and development for the Company for consideration of $110,706, an additional loan was made to Meditecnic SA of  $243,528.  The Company realized a $62 loss due to the decrease in market value of publicly traded securities it owns.   PART II.  OTHER INFORMATION  Item 1. LEGAL PROCEEDINGS  -  None  Item 2. CHANGES IN SECURITIES - None  Item 3. DEFAULTS UPON SENIOR SECURITIES - None  Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS - None  Item 5. OTHER INFORMATION - None  Item 6. EXHIBITS --None         SIGNATURES  Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.   MEDITECNIC, INC.    Date: October 6, 2008 By:/s/ Luc Badel Luc Badel Treasurer (chief financial officer and accounting officer and duly authorized officer)